Stabilized formulations of cns compounds
US-2015086629-A1 · Mar 26, 2015 · US
Method of treatment of aggression
US10058556B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10058556-B2 |
| Application number | US-201715782334-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 12, 2017 |
| Priority date | Dec 19, 2008 |
| Publication date | Aug 28, 2018 |
| Grant date | Aug 28, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating impulsive aggression in an attention deficit hyperactivity disorder (ADHD) patient, comprising: administering 10 mg/day to 200 mg/day of molindone to a patient with ADHD as the sole condition and manifesting impulsive aggression not controlled by ADHD treatment. 2. The method of claim 1 , wherein 15 to 120 mg/day of molindone is administered. 3. The method of claim 1 , wherein the administration decreases side effects associated with molindone. 4. The method of claim 3 , wherein the side effects are selected from drowsiness, depression, hyperactivity, euphoria, extrapyramidal reactions, akathisia, akinesia, dystonic syndrome, tardive dyskinesia, tachycardia, nausea, dry mouth, urinary retention, and constipation. 5. The method of claim 1 , wherein the administration results in reduction of undesirable behavior and intolerable side effects. 6. The method of claim 1 , wherein the patient is a child.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Hypnotics; Sedatives · CPC title
Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title
Drugs for disorders of the nervous system · CPC title
- A61K31/5377Primary
not condensed and containing further heterocyclic rings, e.g. timolol · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10058556B2 cover?
- The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity.
- Who is the assignee on this patent?
- Supernus Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5377. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).